Loading people...
Amanda Cashin is an Advisor at Wilson Hill Ventures based in the San Francisco Bay Area. She previously served as the Co-founder and Global Head of Illumina for Startups, where she established the Illumina Accelerator in 2014 and acted as a founding investor in 74 early-stage genomics companies. During her corporate tenure, she expanded the accelerator program to the United Kingdom and partnered to launch the Sequoia Capital China Intelligent Healthcare Genomics Incubator in 2021. Before joining Illumina, Cashin worked as Senior Vice President of Alexandria Venture Investments at Alexandria Real Estate Equities, managing life science investment initiatives. She holds a doctorate in chemical biology from Caltech, where she currently serves on the alumni board of directors. Her career focuses on building and funding science-driven startups across the therapeutics, synthetic biology, and agricultural technology sectors.
Amanda Cashin stands as a pivotal figure within the life sciences investment landscape, serving as an investor at the prestigious Illumina Accelerator. In this capacity, she is instrumental in fostering the next generation of biotech and genomics companies, guiding them from nascent ideas to market-ready solutions. Her work at Illumina Accelerator involves a deep commitment to identifying early-stage startups that are poised to make significant impacts in areas such as precision medicine, diagnostics, synthetic biology, and advanced research tools.
Illumina Accelerator is renowned for its unique model, providing selected startups with access to Illumina's cutting-edge sequencing technology, world-class scientific expertise, and a robust network of mentors and investors. Amanda's role is multifaceted, encompassing due diligence, strategic guidance, and portfolio management. She collaborates closely with founders, helping them refine their scientific and business strategies, navigate regulatory pathways, and secure subsequent funding rounds. Her insights are invaluable for companies aiming to translate complex genomic research into tangible products and services.
While specific details of Amanda Cashin's career background are not publicly detailed, her position at Illumina Accelerator strongly suggests a robust foundation in venture capital, corporate development, or a scientific discipline within the life sciences sector. Professionals in her role typically possess a keen understanding of scientific innovation, market dynamics, and the unique challenges faced by early-stage biotech ventures. This blend of scientific acumen and business savvy enables her to effectively evaluate potential investments and provide strategic support to portfolio companies.
Amanda's investment focus areas are directly aligned with the mission of Illumina Accelerator: to accelerate innovation in genomics. This includes companies developing novel applications for DNA sequencing, single-cell analysis, multi-omics technologies, bioinformatics, and gene editing. While specific notable investments are part of the accelerator's confidential portfolio, Amanda contributes to a diverse group of companies that are pushing the boundaries of what is possible in health and biology. Her efforts help ensure that the most promising scientific breakthroughs receive the resources and guidance needed to thrive, ultimately benefiting patients and researchers worldwide. Through her dedication, Amanda Cashin continues to shape the future of genomics and precision health.
Amanda Cashin is an investor at Illumina Accelerator, focusing on early-stage companies in genomics and life sciences. She helps identify and nurture innovative startups.
Amanda Cashin invests in early-stage companies within the genomics and life sciences sectors. Her focus areas include precision medicine, diagnostics, synthetic biology, and advanced research tools that leverage Illumina's technology.
Amanda Cashin works as an investor at Illumina Accelerator, a program designed to foster and accelerate groundbreaking startups in genomics and related life science fields.
